Kinnate Biopharma Inc. (KNTE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nima M. Farzan
Employees:
70
11975 EL CAMINO REAL, STE 101, SAN DIEGO, CA 92130
8582994699

Kinnate Biopharma focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors.

Data derived from most recent annual or quarterly report
Market Cap 254.389 Million Shares Outstanding44.165 Million Avg 30-day Volume 121.375 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.7
Price to Revenue0.0 Debt to Equity0.0 EBITDA-117.235 Million
Price to Book Value1.2029 Operating Margin0.0 Enterprise Value37.462 Million
Current Ratio13.447 EPS Growth-0.282 Quick Ratio11.736
1 Yr BETA 1.4123 52-week High/Low 15.86 / 3.3 Profit Margin0.0
Operating Cash Flow Growth-25.2853 Altman Z-Score6.1368 Free Cash Flow to Firm -79.117 Million
Earnings Report2023-05-11
View SEC Filings from KNTE instead.

View recent insider trading info

Kinnate Biopharma Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KNTE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KNTE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-03 by WILLIAMS RICHARD THOMAS
  • 4: filed on 2023-03-03 by Meltz Mark A
  • 4: filed on 2023-03-03 by KRISHNAMOHAN NEHA
  • 4: filed on 2023-03-03 by DESIMONE JILL
  • 3: filed on 2023-03-03 by DESIMONE JILL
  • 4: filed on 2023-02-23 by ORBIMED ADVISORS LLC
  • 3: filed on 2023-02-23 by OrbiMed Capital GP VIII LLC
  • 4: filed on 2023-02-22 by GORDON CARL L
  • 4: filed on 2023-02-22 by TANANBAUM JAMES B.
  • 4: filed on 2023-02-22 by FORESITE CAPITAL FUND IV, L.P.

    • Events (8k)

  • 8-K: filed on 2023-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-18:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MELTZ MARK A COO GENERAL COUNSEL SECRETARY

    • Officer
    		 27,286 2023-03-01 4

    WILLIAMS RICHARD THOMAS CHIEF MEDICAL OFFICER

    • Officer
    		 67,295 2023-03-01 4

    KRISHNAMOHAN NEHA CHIEF FINANCIAL OFFICER

    • Officer
    		 67,378 2023-03-01 4

    DESIMONE JILL

    • Director
    		 0 2023-03-01 2

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED CAPITAL GP VIII LLC

    ORBIMED ASIA GP IV, L.P.

    ORBIMED ADVISORS IV LTD

    ORBIMED GENESIS GP LLC

    ORBIMED CAPITAL LLC

    • Director
    • 10% Owner
    		 5,143,629 2023-02-17 1

    GORDON CARL L

    • Director
    • 10% Owner
    		 5,143,629 2023-02-17 2

    TANANBAUM JAMES B.

    • Director
    • 10% Owner
    		 11,938,311 2023-02-17 2

    FORESITE CAPITAL MANAGEMENT IV, LLC

    FORESITE CAPITAL FUND IV, L.P.

    FORESITE CAPITAL FUND V, L.P.

    FORESITE CAPITAL MANAGEMENT V, LLC

    FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

    FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

    • 10% Owner
    		 11,938,311 2023-02-17 1

    ORBIMED CAPITAL GP VIII LLC

    ORBIMED ASIA GP IV, L.P.

    ORBIMED ADVISORS IV LTD

    • Director
    • 10% Owner
    		 550,000 2023-02-17 1

    FARZAN NIMA CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-02-10 2

    MITCHELL DEAN J

    • Director
    		 20,250 2022-06-13 1

    FLAHERTY KEITH T.

    • Director
    		 20,250 2022-06-13 1

    SMALDONE ALSUP LAURIE

    • Director
    		 20,250 2022-06-13 1

    SABZEVARI HELEN

    • Director
    		 20,250 2022-06-13 1

    EPPERLY MELISSA B,

    • Director
    		 20,250 2022-06-13 1

    ROME MICHAEL E

    • Director
    		 20,250 2022-06-13 1

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED GENESIS GP LLC

    ORBIMED CAPITAL LLC

    • Director
    		 3,509,030 2022-02-11 1

    MURPHY ERIC ANTHONY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2021-02-12 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED CAPITAL LLC

    • Director
    • 10% Owner
    		 750,000 2020-12-02 1

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED GENESIS GP LLC

    • Director
    • 10% Owner
    		 0 2020-12-02 1

    KALDOR STEPHEN W

    • Director
    		 1,615,826 2020-12-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DESIMONE JILL - Director

    		2023-03-03 17:54:27 -0500 2023-03-01 A 50,000 a 50,000 direct

    MELTZ MARK A - Officer COO GENERAL COUNSEL SECRETARY

    		2023-03-03 17:57:39 -0500 2023-03-01 F 638 $5.21 d 27,286 direct -4.9116 -15.1277 0.0 1 -32.0236 5

    KRISHNAMOHAN NEHA - Officer CHIEF FINANCIAL OFFICER

    		2023-03-03 17:56:28 -0500 2023-03-01 F 1,721 $5.21 d 67,378 direct -4.9116 -15.1277 0.0 1 -32.0236 5

    WILLIAMS RICHARD THOMAS - Officer CHIEF MEDICAL OFFICER

    		2023-03-03 17:58:44 -0500 2023-03-01 F 638 $5.21 d 67,295 direct -4.9116 -15.1277 0.0 1 -32.0236 5

    TANANBAUM JAMES B. - Director - > 10% Owner see footnote

    		2023-02-22 14:50:23 -0500 2023-02-17 J 1,100,000 a 1,975,001 indirect -2.7553 -15.5592 0.0 1 -16.0454 3

    FORESITE CAPITAL MANAGEMENT IV, LLC - > 10% Owner see footnote

    FORESITE CAPITAL FUND IV, L.P. - > 10% Owner see footnote

    FORESITE CAPITAL FUND V, L.P. - > 10% Owner see footnote

    FORESITE CAPITAL MANAGEMENT V, LLC - > 10% Owner see footnote

    FORESITE CAPITAL OPPORTUNITY FUND V, L.P. - > 10% Owner see footnote

    FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC - > 10% Owner see footnote

    		2023-02-22 14:49:36 -0500 2023-02-17 J 1,100,000 a 1,975,001 indirect -2.7553 -15.5592 0.0 1 -16.0454 3

    GORDON CARL L - Director - > 10% Owner see footnotes

    		2023-02-22 16:30:45 -0500 2023-02-17 A 550,000 a 550,000 indirect -13.6667 -15.0 0.0 1 -15.0 6

    GORDON CARL L - Director - > 10% Owner see footnotes

    		2023-02-22 16:30:45 -0500 2023-02-17 A 550,000 a 550,000 indirect -13.6667 -15.0 0.0 1 -15.0 6

    ORBIMED ADVISORS LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VII LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VIII LLC - Director - > 10% Owner see footnotes

    ORBIMED ASIA GP IV, L.P. - Director - > 10% Owner see footnotes

    ORBIMED ADVISORS IV LTD - Director - > 10% Owner see footnotes

    ORBIMED GENESIS GP LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL LLC - Director - > 10% Owner see footnotes

    		2023-02-23 14:16:09 -0500 2023-02-17 A 550,000 a 550,000 indirect -13.6667 -15.0 0.0 1 -15.0 6

    ORBIMED ADVISORS LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VII LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VIII LLC - Director - > 10% Owner see footnotes

    ORBIMED ASIA GP IV, L.P. - Director - > 10% Owner see footnotes

    ORBIMED ADVISORS IV LTD - Director - > 10% Owner see footnotes

    ORBIMED GENESIS GP LLC - Director - > 10% Owner see footnotes

    ORBIMED CAPITAL LLC - Director - > 10% Owner see footnotes

    		2023-02-23 14:16:09 -0500 2023-02-17 A 550,000 a 550,000 indirect -13.6667 -15.0 0.0 1 -15.0 6

    MELTZ MARK A - Officer COO GENERAL COUNSEL SECRETARY

    		2023-02-14 17:00:56 -0500 2023-02-10 A 215,000 a 215,000 direct

    FARZAN NIMA - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-14 17:00:33 -0500 2023-02-10 A 750,000 a 215,000 direct

    KRISHNAMOHAN NEHA - Officer CHIEF FINANCIAL OFFICER

    		2023-02-14 17:00:27 -0500 2023-02-10 A 215,000 a 215,000 direct

    WILLIAMS RICHARD THOMAS - Officer CHIEF MEDICAL OFFICER

    		2023-02-14 17:00:44 -0500 2023-02-10 A 215,000 a 215,000 direct

    FARZAN NIMA - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-15 11:01:38 -0500 2023-02-10 A 750,000 a 750,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KINNATE BIOPHARMA INC KNTE 2023-03-24 22:15:03 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 21:45:03 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 21:15:03 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 20:45:03 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 20:15:04 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 19:45:03 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 19:15:04 UTC 4.0498 0.7702 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 18:45:04 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 18:15:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 17:45:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 17:15:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 16:45:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 16:15:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 15:45:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 15:15:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 14:45:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 14:15:03 UTC 3.9908 0.8292 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 13:45:03 UTC 3.6425 0.9275 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 13:15:04 UTC 3.6425 0.9275 100000
    KINNATE BIOPHARMA INC KNTE 2023-03-24 12:45:03 UTC 3.6425 0.9275 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund KNTE -400.0 shares, $-2440.0 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments